By InvitationPhase 1

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

Canada1 participantsStarted 2025-11

Plain-language summary

This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy\_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

This is an individual patient expanded access study specific to one individual based on tailor intervention (Mycobacteriophage) Inclusion Criteria: * consent to participation Exclusion Criteria: * non-consent to participation

What they're measuring

Microbiologic: Response

Timeframe: 2 years

Trial details

NCT IDNCT07228702

SponsorVancouver Coastal Health

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2027-10

View on ClinicalTrials.gov More Non-Tuberculous Mycobacterial (NTM) Pneumonia trials